Minimal residual disease (MRD) is the major cause of relapse in multiple myeloma (MM), and measurements of its level can be utilized to determine treatment response and prognosis. Here, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, discusses the impact of MRD status and cytogenetics on the treatment response of MM patients in the Phase III Myeloma XI trial (NCT01554852), which investigated the benefit of lenalidomide maintence therapy. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Myeloma XI trial: impact of MRD on treatment response in MM
